Sign in
CompletedPhase 1/2

Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions

Key facts

Who runs it
Barinthus Biotherapeutics
Where
Belgium, Estonia, and United Kingdom16 sites in 3 countriesChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
108 people enrolled
Started
16 Mar 2021
Ended
16 Jan 2024
Type of study
Interventional, 9 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ChAdOx1-HPV
  • MVA-HPV
  • Placebo
Record updated
28 August 2025

Who can take part

Age
25 years to 55 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Females aged ≥25 and ≤55 years of age at screening
  • Persistent hrHPV infection defined as a documented cervical infection with hrHPV type(s) in the 6 to 18 months prior to screening and confirmed at screening (participants in the main and expansion phases only). Participants in the lead-in phase are only required to have the screening result
  • Low- grade cervical lesion (CIN1 or HPV-related change only) confirmed by histology and/or cytology report within the 1 year prior to screening
  • Not pregnant or breast feeding and one of the following:; Of non-childbearing potential (i.e. women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses for at least 12 months and without an alternative medical cause); Of childbearing potential but agrees to practice highly effective contraception for 4 weeks prior to administration of the first dose of study vaccine and throughout the study until 8 weeks after administration of the second dose. Highly effective methods of contraception include one or more of the following:; Male partner who is sterile (medically effective vasectomy) prior to the female participant's entry into the study and is the sole sexual partner for the female participant; Hormonal (oral, intravaginal, transdermal, implantable or injectable). Progestogen-only hormonal contraceptives without inhibition of ovulation are not considered to be highly effective; An intrauterine hormone releasing system; An intrauterine device; Bilateral tubal occlusion; Sexual abstinence, only if the participant refrains from heterosexual intercourse during the entire study period and it is the usual lifestyle of the participant
  • Willing to abstain from sexual activity for 48 hours prior to all swabbing procedures

Who cannot take part

  • Evidence of high grade cervical lesions by colposcopy or by Papanicolaou (Pap) smear test in the 1 year prior to screening
  • Receipt of any investigational drug or investigational vaccine within 3 months prior to administration of ChAdOx1-HPV on Day 0, or prior participation in a clinical study of any HPV vaccine
  • Receipt of any adenoviral based vaccine within 3 months prior to administration of ChAdOx1 HPV on Day 0, or plan to receive an adenoviral-based vaccine within 3 months after Day 0
  • Receipt of any live vaccines within the 30 days or inactivated vaccine within the 14 days prior to administration of ChAdOx1-HPV on Day 0 or planned to occur in the 2 months after the Day 0 vaccination
  • Current or history of illicit drug use within the 6 months prior to screening
  • Current or history of severe alcohol abuse within the 6 months prior to screening
  • Presence of any significant acute or chronic, uncontrolled medical (or psychiatric) illness, including blood dyscrasias
  • Immunosuppression as a result of underlying illness or treatment including:; Use of high dose corticosteroids ( >10 mg/day prednisone or equivalent) for ≥7 days (inhaled, otic and ophthalmic corticosteroids are permitted); Primary immune deficiency disease; Use of synthetic or biologic disease-modifying antirheumatic drugs; History of bone marrow or solid organ transplant; History of any other clinically significant autoimmune or immunosuppressive disease
  • Positive diagnostic tests (for human immunodeficiency virus, hepatitis B or hepatitis C) indicating chronic infection
  • Any history of anaphylaxis in reaction to vaccination or history of allergic reactions likely to be exacerbated by any component of the vaccine, e.g. severe allergy to eggs
  • Current known infection with severe acute respiratory syndrome coronavirus 2 (SARS CoV-2)
  • Any laboratory test which is abnormal and deemed by the Investigator to be clinically significant which will potentially affect the participation in the study
  • Any other finding that, in the opinion of the Investigator, deems the participant unsuitable for the study

This trial has no sites in United States.

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

A Phase 1b/2 multi-centre study evaluating the safety, efficacy and immunogenicity of prime-boost vaccines ChAdOx1-HPV and MVA-HPV in women with HPV related low grade cervical lesions.

The 9 groups in the trial

  • Lead-in Group A ChAdOx1-HPV low dose and MVA-HPV low doseTreatment being tested

    Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^8 vp) and MVA-HPV (1 x 10\^7 pfu)

    Treatment: ChAdOx1-HPV and MVA-HPV

  • Lead-in Group B ChAdOx1-HPV mid dose and MVA-HPV low doseTreatment being tested

    Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^9 vp) and MVA-HPV (1 x 10\^7 pfu)

    Treatment: ChAdOx1-HPV and MVA-HPV

  • Lead-in Group C ChAdOx1-HPV high dose and MVA-HPV high doseTreatment being tested

    Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^10) vp and MVA-HPV (1 x 10\^8 pfu)

    Treatment: ChAdOx1-HPV and MVA-HPV

  • Group 1 ChAdOx1-HPV mid dose and MVA-HPV low doseTreatment being tested

    Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^9 vp) and MVA-HPV (1 x 10\^7 pfu)

    Treatment: ChAdOx1-HPV and MVA-HPV

  • Group 2 ChAdOx1-HPV high dose and MVA-HPV low doseTreatment being tested

    Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^10 vp) and MVA-HPV (1 x 10\^7 pfu)

    Treatment: ChAdOx1-HPV and MVA-HPV

  • Group 3 ChAdOx1-HPV low dose and MVA-HPV high doseTreatment being tested

    Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^8 vp) and MVA-HPV (1 x 10\^8 pfu)

    Treatment: ChAdOx1-HPV and MVA-HPV

  • Group 4 ChAdOx1-HPV mid dose and MVA-HPV high doseTreatment being tested

    Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^9 vp) and MVA-HPV (1 x 10\^8 pfu)

    Treatment: ChAdOx1-HPV and MVA-HPV

  • Group 5 ChAdOx1-HPV high dose and MVA-HPV high doseTreatment being tested

    Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^10 vp) and MVA-HPV (1 x 10\^8 pfu)

    Treatment: ChAdOx1-HPV and MVA-HPV

  • Group 6 Placebo SalinePlacebo, for comparison

    Sodium Chloride (0.9%)

    Treatment: Placebo

Results explained

A paper that names this trial, explained in plain words.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1b/2, Randomised, Placebo-controlled, Dose-ranging Study to Evaluate Safety, Tolerability and Immunogenicity of a Chimpanzee Adenovirus (ChAdOx1)-Vectored Multigenotype High Risk Human Papillomavirus (hrHPV) Vaccine and Modified Vaccinia Ankara (MVA)-Vectored Multigenotype hrHPV Vaccine in Women With Low-grade HPV-related Cervical Lesions
Publications
Record updated
28 August 2025